PAIN
Volume 151, Issue 3 , Pages 617-624 , December 2010

A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain

  • Russell K. Portenoy

      Affiliations

    • Beth Israel Medical Center, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA. Tel.: +1 (212) 844 1505; fax: +1 (212) 844 1503.
    • ,
  • Allen W. Burton

      Affiliations

    • The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Nashat Gabrail

      Affiliations

    • Gabrail Cancer Center, Canton, OH, USA
    • ,
  • Donald Taylor

      Affiliations

    • Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA, USA
    • ,
  • on behalf of the Fentanyl Pectin Nasal Spray 043 Study Group

Received 20 November 2009 ,Revised 26 July 2010 ,Accepted 27 July 2010.

References 

  1. Bennett DS, Burton AW, Fishman S, Fortner BV, McCarberg BH, Miaskowski C, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Management. Pharm Ther. 2005;30:354–361
  2. Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177–183
  3. Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998;16:3238–3245
  4. Collins SL, Faura CC, Moor RA, McQuay HJ. Peak plasma concentration after oral morphine: a systematic review. J Pain Symptom Manage. 1998;16:388–402
  5. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46:759–770
  6. Darwish M, Kirby M, Robertson P, Hellriegel E, Jiang JG. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet. 2006;45:843–850
  7. Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage. 2001;22:820–825
  8. Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage. 2005;30:496–497
  9. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage. 2003;25:406–411
  10. Fortner BV, Demarco G, Irving G, Ashley J, Keppler G, Chavez J, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25:9–18
  11. Gordon SR, Berkey DB, Call RL. Dental need among hospice patients in Colorado: a pilot study. Gerodontics. 1985;1:125–129
  12. Illum L. Nasal drug delivery – possibilities, problems and solutions. J Control Release. 2003;87:187–198
  13. Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200micrograms for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177–1191
  14. Lennernäs B, Hedner T, Holmberg M, Bredenberg S, Nyström C, Lennernäs H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005;59:249–253
  15. Lemmens HJ, Wada DR, Munera C, Eltahtawy A, Stanski DR. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials. 2006;27:165–173
  16. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94:832–839
  17. Moksnes K, Fredheim OM, Klepstad P, Kaasa S, Angelsen A, Nilsen T, et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?. Eur J Clin Pharmacol. 2008;64:497–502
  18. Ploner M, Lee MC, Wiech K, Bingel U, Tracey I. Prestimulus functional connectivity determines pain perception in humans. Proc Natl Acad Sci USA. 2010;107:355–360
  19. Portenoy R, Bruns D, Shoemaker B, Shoemaker S. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, 1: prevalence and characteristics. J Opioid Manag. 2010;6:97–108
  20. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–281
  21. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–134
  22. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999;79:303–312
  23. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805–811
  24. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327–334
  25. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol. 2008;66:266–275
  26. Svendsen KB, Andersen S, Arnason S, Arner S, Breivik H, Heiskanen T, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195–206
  27. Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig. 2009;29:647–654
  28. Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med. 2003;17:219–221
  29. Watson A, El-Deredy W, Iannetti GD, Lloyd D, Tracey I, Vogt BA. Placebo conditioning and placebo analgesia modulate a common brain network during pain anticipation and perception. Pain. 2009;145:24–30
  30. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv. 2009;6:543–552

PII: S0304-3959(10)00450-1

doi: 10.1016/j.pain.2010.07.028

PAIN
Volume 151, Issue 3 , Pages 617-624 , December 2010

Article Tools

* Image Usage & Resolution